Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Multiple Sclerosis News

Disappointing Trials Results For Sativex, UK

Main Category: Multiple Sclerosis
Article Date: 18 Apr 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 and a half stars

4.17 (6 votes)

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

GW Pharmaceuticals, which makes Sativex - an oral spray containing a cannabis extract - has released disappointing results of a trial testing the drug's benefits in treating pain in people with multiple sclerosis (MS).

The study involved 339 people experiencing neuropathic pain due to MS who have achieved inadequate pain relief with existing therapies. Half of the people in the study taking Sativex reported their pain reduced by at least 30 per cent, however the response to the placebo treatment was unusually high, making the actual benefits of the drug difficult to assess.

The latest results mean that the drug will not be made widely available to people with MS until it proves its efficacy in further trials. Other trials are currently underway looking at the effectiveness of Sativex for spasticity in people with MS.

Dr Lee Dunster, Head of Research and Information at the MS Society, said: "These results do not provide clear evidence as to the benefits of Sativex in treating pain in MS and well designed clinical trials are needed to assess the effectiveness of this therapy. We look forward to the results published later this year investigating the effect of Sativex on spasticity in people with MS."

A high placebo response during a clinical trial may occur because symptoms are eased by the simple belief that a treatment will work.

GW Pharmaceuticals stated that people with MS using the placebo took significantly more doses than those taking Sativex, confounding the overall comparison. Last year the firm adopted a fixed target dose approach in other studies of the drug, testing its effect on spasticity and cancer pain, which should prevent this situation occurring in future trials.

MS Society




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Hydrangea Root Shows Promise In Treating Autoimmune Disorders
05 Jun 2009
US researchers found that a drug made from the root of the hydrangea plant, which has for centuries been used in Chinese medicine, showed promising results in treating autoimmune disorders such as rheumatoid arthritis...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

An MS Drug Back on the Market image An MS Drug Back on the Market

After being suspended from the market for safety reasons, natalizumab is again available for the treatment of multiple sclerosis. Safeguards are in place because of a small risk in developing a serious brain infection. Should you consider taking this drug...

View more videos...